Compounds > n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide
Page last updated: 2024-09-02

n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide and Leucocythaemia

n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide has been researched along with Leucocythaemia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atwell, GJ; Baguley, BC; Denny, WA; Finlay, GJ; Gamage, SA; Spicer, JA1
Baguley, BC; Finlay, GJ; Marshall, E; Matthews, JH; Paull, KD1
Baguley, BC; Finlay, GJ1
Baguley, BC; Finlay, GJ; Riou, JF1
Baguley, BC; Davey, MW; Davey, RA; Hargrave, RM; Harvie, RM; Su, GM1

Other Studies

5 other study(ies) available for n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide and Leucocythaemia

ArticleYear
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    Journal of medicinal chemistry, 1997, Jun-06, Volume: 40, Issue:12

    Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Leukemia; Leukemia P388; Lung Neoplasms; Mice; Molecular Structure; Neoplasm Transplantation; Rats; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured

1997
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:5

    Topics: Acridines; Aminoacridines; Antineoplastic Agents; DNA Topoisomerases, Type I; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Leukemia; Melanoma; Tumor Cells, Cultured

1993
Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours.
    Clinical and experimental pharmacology & physiology, 1995, Volume: 22, Issue:11

    Topics: Acridines; Antineoplastic Agents; Camptothecin; Cell Cycle; Drug Design; Drug Screening Assays, Antitumor; Humans; Leukemia; Paclitaxel; Tumor Cells, Cultured

1995
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:4

    Topics: Acridines; Amsacrine; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Tumor Cells, Cultured

1996
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
    Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:5

    Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Line; Cell Survival; Daunorubicin; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin; Leukemia; Paclitaxel; Phenotype; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Verapamil

1997